MISE & Agrave; DAY
WASHINGTON | Moderna announced on Friday its intention to develop a specific booster dose for the new Omicron variant of COVID-19, detected in South Africa and deemed “of concern” by the WHO. & nbsp;
< p> “Moderna will quickly develop a vaccine candidate for a booster dose specific to the Omicron variant,” the US company said in a statement.
This announcement is part of a strategy to work on specific booster doses for variants of concern, according to Moderna.
“In 2020-2021, this has already included booster doses for Delta variants and Beta, ”the company said, saying it“ has repeatedly demonstrated its ability to get new candidates into clinical trials in 60-90 days ”.
“ From the beginning we said that to fight pandemic, it was imperative to be proactive in the face of the evolution of the virus, ”said Moderna boss Stéphane Bancel, quoted in the press release.
“The mutations of the Omicron variant are worrying and for several days we have been moving as fast as possible to execute our strategy to fight this variant”, he added.
Potentially very contagious and with mutations The new variant is causing global concern as it spreads out of South Africa, prompting the world to gradually close its borders to southern Africa.
In Europe, Belgium has detected a first case. A case was reported in Hong Kong and one in Israel, on a person returning from Malawi.
The German laboratory BioNTech, allied with Pfizer, said to study this new variant, and to wait “at the latest in two weeks ”of initial results of studies that will determine if it is capable of escaping vaccine protection.
It will take“ several weeks ”to understand the level of transmissibility and virulence of the new variant, said the WHO spokesperson on Friday. & nbsp;
For the European Medicines Agency (EMA), it is “premature” to plan an adaptation of the vaccines to the Omicron variant. & nbsp ;
SEE ALSO … & nbsp;